Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20100812667external-prioritypatent/EP2470671B1/en
Application filed by Regeneron Pharmaceuticals, Inc.filedCriticalRegeneron Pharmaceuticals, Inc.
Publication of CY1116009T1publicationCriticalpatent/CY1116009T1/en
Αντίσωμα αντικίνη το οποίο προσδένεται σε δύο, τρεις, τέσσερεις, πέντε ή περισσότερες χημειοκίνες CC όπως RANTES/CCL5, MIP-1a/CCL3 και MIP-1β/CCL4 ή MCP-1/CCL2. Δημοσιεύονται επίσης μέθοδοι για ωρίμανση συγγένειας και εξανθρωπισμό αντισωμάτων αντικινών καθώς η παραγωγή κυτταρικών σειρών υβριδώματος που παράγουν αντισώματα αντικινών διαμέσου διαδοχικής ανοσοποίησης.Antibody which binds to two, three, four, five or more CC chemokines such as RANTES / CCL5, MIP-1a / CCL3 and MIP-1β / CCL4 or MCP-1 / CCL2. Methods for affinity maturation and humanization of antibody antibodies as well as the production of hybridoma cell lines that produce antibody antibodies through sequential immunization are also published.
CY20151100169T2009-08-282015-02-18
ANTIBODIES OF ANTIQUES RELATED TO MULTIPLE CHEMICALS CC
CY1116009T1
(en)